Biophan Completes Acquisition of AMRIS

Biophan Technologies, a developer of next-generation biomedical technology, announced completion of the acquisition of a majority interest in AMRIS, bringing Biophan exclusive access to key patents in magnetic resonance imaging (MRI) technology.

AMRIS, an innovator in MRI-safe and image-compatible medical devices and technology solutions, possesses a suite of technology patents that enable effective MRI imaging of a range of important medical devices, including stents and other vascular implants.

The newly acquired AMRIS will be renamed Biophan-Europe, and will serve as Biophan's chief European marketing and research presence. AMRIS subsidiary, MRC, was included in the acquisition. The principals and personnel from AMRIS and its MRC subsidiary bring existing contractual and consulting agreements with many of the world's leading biomedical device and MRI machine manufacturers. As a result, the acquisition significantly expands Biophan's international technology and business relationships in the European medical device industry and the worldwide scientific community.